Identifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.189.975 |
Chemical and physical data | |
Formula | C15H17N3O2 |
Molar mass | 271.320 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
PHA-543,613 is a drug that acts as a potent and selective agonist for the α7 subtype of neural nicotinic acetylcholine receptors, with a high level of brain penetration and good oral bioavailability. It is under development as a possible treatment for cognitive deficits in schizophrenia. It reduces excitotoxicity and protects striatal dopaminergic neurons in rat models. It also potentiates cognitive enhancement from memantine, decreases dynorphin release and inhibits GSK-B3.
See also
References
- Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, et al. (July 2006). "Discovery of N-oct-3-yl]furopyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship". Journal of Medicinal Chemistry. 49 (14): 4425–36. doi:10.1021/jm0602413. PMID 16821801.
- Foucault-Fruchard L, Doméné A, Page G, Windsor M, Emond P, Rodrigues N, Dollé F, Damont A, Buron F, Routier S, Chalon S, Antier D (July 2017). "Neuroprotective effect of the alpha 7 nicotinic receptor agonist PHA 543613 in an in vivo excitotoxic adult rat model". Neuroscience. 356: 52–63. doi:10.1016/j.neuroscience.2017.05.019. PMID 28527955. S2CID 4827887.
- Sérrière S, Doméné A, Vercouillie J, Mothes C, Bodard S, Rodrigues N, Guilloteau D, Routier S, Page G, Chalon S (2015). "Assessment of the Protection of Dopaminergic Neurons by an α7 Nicotinic Receptor Agonist, PHA 543613 Using [(18)F]LBT-999 in a Parkinson's Disease Rat Model". Frontiers in Medicine. 2: 61. doi:10.3389/fmed.2015.00061. PMC 4556971. PMID 26389120.
- Bruszt N, Bali ZK, Tadepalli SA, Nagy LV, Hernádi I (August 2021). "Potentiation of cognitive enhancer effects of Alzheimer's disease medication memantine by alpha7 nicotinic acetylcholine receptor agonist PHA-543613 in the Morris water maze task". Psychopharmacology. 238 (11): 3273–3281. doi:10.1007/s00213-021-05942-4. PMC 8605977. PMID 34387707.
- Bali ZK, Bruszt N, Tadepalli SA, Csurgyók R, Nagy LV, Tompa M, Hernádi I (2019). "Cognitive Enhancer Effects of Low Memantine Doses Are Facilitated by an Alpha7 Nicotinic Acetylcholine Receptor Agonist in Scopolamine-Induced Amnesia in Rats". Frontiers in Pharmacology. 10: 73. doi:10.3389/fphar.2019.00073. PMC 6371842. PMID 30804787.
- Ji L, Chen Y, Wei H, Feng H, Chang R, Yu D, Wang X, Gong X, Zhang M (July 2019). "Activation of alpha7 acetylcholine receptors reduces neuropathic pain by decreasing dynorphin A release from microglia". Brain Research. 1715: 57–65. doi:10.1016/j.brainres.2019.03.016. PMID 30898676. S2CID 81981843.
- Krafft PR, Altay O, Rolland WB, Duris K, Lekic T, Tang J, Zhang JH (March 2012). "α7 nicotinic acetylcholine receptor agonism confers neuroprotection through GSK-3β inhibition in a mouse model of intracerebral hemorrhage". Stroke. 43 (3): 844–50. doi:10.1161/STROKEAHA.111.639989. PMC 3293395. PMID 22207510.
Psychoanaleptics: Anti-dementia agents (ATC code N06D and others) | |
---|---|
AChE inhibitor medications | |
Other medications | |
Experimental BACE inhibitors |